Apexigen raises $20m for CD40-targeting immunotherapy
Apexigen raised $20 million in a Series A1 funding round to finance development of APX005, a CD40 agonist and immunotherapeutic candidate.
Apexigen raised $20 million in a Series A1 funding round to finance development of APX005, a CD40 agonist and immunotherapeutic candidate.